N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder
الكلمات الدالة
نبذة مختصرة
تواريخ
آخر التحقق: | 07/31/2019 |
تم الإرسال لأول مرة: | 07/26/2010 |
تم إرسال التسجيل المقدر: | 07/27/2010 |
أول نشر: | 07/28/2010 |
تم إرسال آخر تحديث: | 08/13/2019 |
آخر تحديث تم نشره: | 09/05/2019 |
تاريخ أول النتائج المقدمة: | 07/21/2019 |
تاريخ أول نتائج مراقبة الجودة المقدمة: | 08/13/2019 |
تاريخ أول النتائج المنشورة: | 09/05/2019 |
تاريخ بدء الدراسة الفعلي: | 06/30/2012 |
تاريخ الإنجاز الأساسي المقدر: | 02/12/2017 |
التاريخ المتوقع لانتهاء الدراسة: | 02/14/2018 |
حالة أو مرض
التدخل / العلاج
Drug: N-Acetylcysteine
Other: Placebo
مرحلة
مجموعات الذراع
ذراع | التدخل / العلاج |
---|---|
Experimental: N-Acetylcysteine N-Acetylcysteine effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. | Drug: N-Acetylcysteine 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. |
Placebo Comparator: Placebo Placebo effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial. | Other: Placebo 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial. |
معايير الأهلية
الأعمار المؤهلة للدراسة | 8 Years إلى 8 Years |
الأجناس المؤهلة للدراسة | All |
يقبل المتطوعين الأصحاء | نعم |
المعايير | Inclusion Criteria: - Children aged 8-17 years. - Primary diagnosis of OCD. - Duration of OCD greater than 6 months. - Significant Current OCD symptoms: Current CY-BOCS score > or = 16. Exclusion Criteria: - Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental disorder or mental retardation (IQ<70). - Recent change (less than 4 weeks) in medications that have potential effects on OCD severity (such as Selective Serotonin Reuptake Inhibitors, clomipramine, naltrexone, lithium, psychostimulants, anxiolytics, or antipsychotics). Medication change is defined to include either dose changes or medication discontinuation. - Recent change in behavioral treatment for OCD or comorbid conditions within the last 4 weeks or initiation of behavioral therapy for tics within the last 12 weeks. - Asthma requiring medication use within the last 3 months (case reports have linked intravenous NAC administration with asthma exacerbation) - Known hypersensitivity or previous anaphylactoid reaction to acetylcysteine or any components in its preparation. - Positive pregnancy test or drug screening test. - Previous use of N-acetylcysteine (dose greater than 600mg for more than 2 weeks). - Previous history or suspicion of cystinuria because of a possibility of forming kidney stones. |
النتيجة
مقاييس النتائج الأولية
1. OCD Severity at 12 Weeks [12 weeks]
مقاييس النتائج الثانوية
1. Overall Improvement at 12 Weeks [12 weeks]